Second Sight Medical Products EBIT

Second Sight Medical Products (EYES) currently reports a EBIT of $-28M as of March 2026. That compares with $-29M in the prior-year period — up 3.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Second Sight Medical Products's EBIT history and peer comparisons.

Second Sight Medical Products's EBIT increased from $-29M to $-28M — a 3.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Second Sight Medical Products's EBIT of $-28M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Second Sight Medical Products reported $-28M in EBIT as of March 2026. That compares with $-29M in the prior-year period — up 3.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Second Sight Medical Products, and consider following EYES for alerts when major investors trade the stock.